Dokumentuaren aipamena
APA (7th ed.) Zitazioa
Assunção, S. S., Sperling, R. A., Ritchie, C., Kerwin, D. R., Aisen, P. S., Lansdall, C., . . . Cummings, J. (2022). Meaningful benefits: A framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease. BMC.
Ondo kopiatu da
Kopiatzeak huts egin du
Chicago Style (17th ed.) Zitazioa
Assunção, Sheila Seleri, Reisa A. Sperling, Craig Ritchie, Diana R. Kerwin, Paul S. Aisen, Claire Lansdall, Alireza Atri, eta Jeffrey Cummings. Meaningful Benefits: A Framework to Assess Disease-modifying Therapies in Preclinical and Early Alzheimer’s Disease. BMC, 2022.
Ondo kopiatu da
Kopiatzeak huts egin du
MLA (9th ed.) Zitazioa
Assunção, Sheila Seleri, et al. Meaningful Benefits: A Framework to Assess Disease-modifying Therapies in Preclinical and Early Alzheimer’s Disease. BMC, 2022.
Ondo kopiatu da
Kopiatzeak huts egin du
Kontuz: berrikusi erreferentzia hauek erabili aurretik.